Detalhe da pesquisa
1.
Prognostic gene expression signature for high-grade serous ovarian cancer.
Ann Oncol
; 31(9): 1240-1250, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32473302
2.
Serum selenium levels predict survival after breast cancer.
Breast Cancer Res Treat
; 167(2): 591-598, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29043463
3.
The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer.
Clin Genet
; 93(5): 1063-1068, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29206279
4.
The impact of an expanded genetic testing program and selective oophorectomy on the incidence of ovarian cancer in West Pomerania.
Clin Genet
; 91(2): 322-327, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27623744
5.
New EPCAM founder deletion in Polish population.
Clin Genet
; 92(6): 649-653, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28369810
6.
The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients.
Breast Cancer Res Treat
; 156(2): 371-8, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26983446
7.
Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland.
Hered Cancer Clin Pract
; 14: 5, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26843898
8.
Cumulative effects of genetic markers and the detection of advanced colorectal neoplasias by population screening.
Clin Genet
; 88(3): 234-40, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25117299
9.
Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland.
Clin Genet
; 88(4): 366-70, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25330149
10.
Recurrent mutations of BRCA1 and BRCA2 in Poland: an update.
Clin Genet
; 87(3): 288-92, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24528374
11.
Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study.
Br J Cancer
; 110(2): 530-4, 2014 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-24292448
12.
Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study.
Ann Oncol
; 25(6): 1152-8, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24692579
13.
Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients.
Breast Cancer Res Treat
; 147(2): 401-5, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25129345
14.
Survival from breast cancer in patients with CHEK2 mutations.
Breast Cancer Res Treat
; 144(2): 397-403, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24557336
15.
A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers.
Curr Oncol
; 21(2): 64-8, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24764694
16.
Xeroderma pigmentosum genes and melanoma risk.
Int J Cancer
; 133(5): 1094-100, 2013 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23436679
17.
A personalised approach to prostate cancer screening based on genotyping of risk founder alleles.
Br J Cancer
; 108(12): 2601-9, 2013 Jun 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-23722471
18.
An inherited NBN mutation is associated with poor prognosis prostate cancer.
Br J Cancer
; 108(2): 461-8, 2013 Feb 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-23149842
19.
Clinical characteristics of breast cancer in patients with an NBS1 mutation.
Breast Cancer Res Treat
; 141(3): 471-6, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24072268
20.
Parental origin of mutation and the risk of breast cancer in a prospective study of women with a BRCA1 or BRCA2 mutation.
Clin Genet
; 84(1): 43-6, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23066998